

Q3 2014 SALES UP 11.0%

Lure, October 23, 2014 – The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Sales (€m)	2014	2013	Change (reported data)	Change at constant exchange rates	Change at constant exchange rates and consolidation scope
Q1	73.2	75.5	-3.0%	-0.1%	-0.1%
Q2	76.2	70.0	+8.8%	+11.9%	+5.5%
Q3	82.2	74.1	+11.0%	+11.1%	+4.6%
Aggregate 9-month sales	231.6	219.6	+5.5%	+7.5%	+3.3%

Sales of pet products were up 6.7% for the first nine months of the year, while sales of livestock products rose by 4.2%.

Sales increased in all of the Group's strategic territories: +5.8% in Europe, +3.6% in the Americas, boosted by the Bioniche acquisition and +7.9% in the Asia Pacific region.

Sales of reference products increased by 14.6% for the first nine months of 2014 and accounted for 47.2% of sales for the period, compared to 43.4% for the same period last year. These products continued to drive the Group's growth.

"During the third quarter, we have been able to grasp opportunities in a European market which is showing recovery signals", Vétoquinol CEO Matthieu Frechin said.

The Vétoquinol Group ranked first in the 6th round of the 2014 Gaia Index for companies generating sales of between €150 to €500 million, and fourth in the industrial sector. The Gaia Index is the SRI index for mid-cap stocks. It is compiled by Ethifinance with the support of the SFAF (French Financial Analysts' Association) and MiddleNext. *"This ranking recognizes our commitment to social responsibility; this prize also reflects our desire for both financial and non-financial transparency", Matthieu Frechin added.*

Operating results for the first nine months of 2014 continued to strengthen the Group's fundamentals.

Next update: 2014 full-year sales on January 22, 2015 (after market close)

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 1,977 people.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: +33 (0)3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations and Media Relations

Emmanuel DOVERGNE

Tel.: +33 (0)1 56 43 44 63

emmanuel.dovergne@keima.fr